Edwards Lifesciences price target raised to $95 from $89 at RBC Capital

RBC Capital raised the firm’s price target on Edwards Lifesciences (EW) to $95 from $89 and keeps an Outperform rating on the shares. The company delivered a Q3 sales and earnings upside surprise of 4%/12%, driven by TAVR outperformance and TMTT/surgery beats, the analyst tells investors in a research note. Sentiment on Edwards Lifesciences has shifted positively of late post TCT updates and Q3 print as several of its catalysts take hold for a multi-year runway, RBC added.